Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2018-2022
About Diffuse Large B-Cell Lymphoma
DLBCL is a cancer of B-lymphocytes. It is the most common type of NHL among adults. It is an aggressive (fast-growing), complex, and difficult-to-treat form of NHL, which refers to a group of cancers of the lymphatic system.
Technavio’s analysts forecast the Global DLBCL Therapeutics Market to grow at a CAGR of 7.64% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the DLBCL therapeutics market. To calculate the market size, the report considers the revenue generated from the application of DLBCL therapeutics across the globe.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report - Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2018-2022
Technavio recognizes the following companies as the key players in the global DLBCL therapeutics market: F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Pfizer, and Spectrum Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the technological advances. Companies are focusing on developing new technologies and innovative therapies which can overcome current challenges in the treatment of various cancers, including DLBCL.”
According to the report, one driver influencing this market is the increasing incidences of DLBCL. DLBCL is a fast-growing and common type of NHL among adults. The incidence of DLBCL is increasing globally and can be fatal if untreated.
Further, the report states that one challenge affecting this market is the high cost of treatment. The cost of chemotherapy, laboratory tests, and oral medications for the treatment of DLBCL are high which is a major challenge for the growth of the market.
F. Hoffmann-La Roche
Merck Sharp & Dohme